Investors

Investors

Novadip is a clinical stage, pre-commercial company that has raised $88M in Series A/B + Non-Dilutive Funding to date, has an FDA Priority Review Voucher and 9 patents covering products and technology.

Novadip is reimagining the standard of care for tissue regeneration with a single treatment cure. Founded in 2013, the team is leveraging its 3M3 tissue regeneration platform to fuel its lead development products that accelerate healing of large bone defects, bone non-union and spine fusion in a single treatment.

Corporate Presentation

More information about the company, the 3M3 tissue regeneration platform and our lead development programs can be found in our corporate presentation.

Recent News

Events & Roadshows

Why Novadip?

Disruptive Product Platform

  • Novel utilization of adipose cells for single treatment cures
  • Potential to address unmet clinical needs in tissue repair and oncology
  • Multi-billion-dollar market opportunity across three product classes

Strong Foundation

  • Clinical outcomes in 50+ patients provide platform validation
  • Patents across nine families; additional patents pending worldwide
  • Established GMP production can be leveraged across platforms

Management Strength

  • Passionate leadership supported by renowned scientific advisory board
  • Demonstrated ability to raise capital in Series A/B rounds
  • Secured eligibility for priority review voucher worth >$100M

Significant Investment Upside Potential

  • Portfolio offers multiple partnering, licensing and acquisition opportunities
  • Substantial non-dilutive funding provides leverage to secure new investment

Highlights

  • Our Mission: Develop a new class of regenerative tissue products that accelerate healing of large bone defects, bone non-union and spine fusion in a single treatment
  • Clinical stage with three therapeutic product classes
  • 50+ procedures completed for bone reconstruction
  • $88 million Series A/B and non-dilutive funding
  • Nine patents covering products and technology
  • One FDA Priority Review Voucher, upon potential approval of NVD-003
  • Total addressable market of $13.5 billion
  • GMP-certified manufacturing facility and supply chain platform can rapidly deliver stable autologous and allogeneic tissue repair products around the globe
  • Our Mission: Develop a new class of regenerative tissue products that accelerate healing of large bone defects, bone non-union and spine fusion in a single treatment
  • Clinical stage with three therapeutic product classes
  • 50+ procedures completed for bone reconstruction
  • $88 million Series A/B and non-dilutive funding
  • Nine patents covering products and technology
  • One FDA Priority Review Voucher, upon potential approval of NVD-003
  • Total addressable market of $13.5 billion
  • GMP-certified manufacturing facility and supply chain platform can rapidly deliver stable autologous and allogeneic tissue repair products around the globe

Shareholders

New Science Ventures

CRCP Lifescience Fund

SRIW Investment for Growth

VIVES Inter University Fund

Fund+ Impacting Life Sciences

New Science Ventures

CRCP Lifescience Fund

SRIW Investment for Growth

VIVES Inter University Fund

Fund+ Impacting Life Sciences

Contact Us

We’d love to discuss investment opportunities with Novadip. Reach out to our investor relations team today.

What’s New

Read media coverage on Novadip including insights from our executive leadership team.

Careers

We work together as one team and are committed to developing and delivering groundbreaking treatments for patients.

Pipeline

Learn about our pipeline of allogeneic and autologous cell-based therapy product candidates.

About Us

Our mission is to develop a new class of regenerative tissue products that accelerate healing in a single treatment.